Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors : A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
The study consists of 2 parts, a dose-escalation part (Phase 1) and an expansion part (Phase 2). Both parts will enroll participants with advanced non-resectable NSCLC, advanced non-resectable thyroid cancer and other advanced solid tumors that have progressed following standard systemic therapy, have not adequately responded to standard systemic therapy, or the participants must be intolerant to or the Investigator has determined that treatment with standard therapy is not appropriate, or there must be no accepted standard therapy for their disease..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 11. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: January 31, 2017, Last downloaded: ClinicalTrials.gov processed this data on April 17, 2024, Last updated: April 17, 2024 |
|---|
| Study ID: |
NCT03037385 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG002354640 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG002354640 | ||
| 003 | DE-627 | ||
| 005 | 20240417010416.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG002354640 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT03037385 | ||
| 035 | |a (UBBS_Klinische_Studien)BO42863 | ||
| 035 | |a (UBBS_Klinische_Studien)2016-004390-41 | ||
| 035 | |a (UBBS_Klinische_Studien)BLU-667-1101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors |b A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: January 31, 2017, Last downloaded: ClinicalTrials.gov processed this data on April 17, 2024, Last updated: April 17, 2024 | ||
| 520 | |a The study consists of 2 parts, a dose-escalation part (Phase 1) and an expansion part (Phase 2). Both parts will enroll participants with advanced non-resectable NSCLC, advanced non-resectable thyroid cancer and other advanced solid tumors that have progressed following standard systemic therapy, have not adequately responded to standard systemic therapy, or the participants must be intolerant to or the Investigator has determined that treatment with standard therapy is not appropriate, or there must be no accepted standard therapy for their disease. | ||
| 650 | 2 | |a Carcinoma | |
| 650 | 2 | |a Neoplasms | |
| 650 | 2 | |a Lung Neoplasms | |
| 650 | 2 | |a Carcinoma, Non-Small-Cell Lung | |
| 650 | 2 | |a Adenocarcinoma | |
| 650 | 2 | |a Colonic Neoplasms | |
| 650 | 2 | |a Thyroid Neoplasms | |
| 650 | 2 | |a Neuroendocrine Tumors | |
| 650 | 2 | |a Colorectal Neoplasms | |
| 650 | 2 | |a Neuroectodermal Tumors | |
| 650 | 2 | |a Neuroectodermal Tumors, Primitive | |
| 650 | 2 | |a Head and Neck Neoplasms | |
| 650 | 2 | |a Gastrointestinal Neoplasms | |
| 650 | 2 | |a Digestive System Neoplasms | |
| 650 | 2 | |a Thyroid Cancer, Papillary | |
| 650 | 2 | |a Neoplasms by Site | |
| 650 | 2 | |a Carcinoma, Neuroendocrine | |
| 650 | 2 | |a Neoplasms by Histologic Type | |
| 650 | 2 | |a Thoracic Neoplasms | |
| 650 | 2 | |a Intestinal Neoplasms | |
| 650 | 2 | |a Neoplasms, Glandular and Epithelial | |
| 650 | 2 | |a Respiratory Tract Neoplasms | |
| 650 | 2 | |a Bronchial Neoplasms | |
| 650 | 2 | |a Carcinoma, Bronchogenic | |
| 650 | 2 | |a Endocrine Gland Neoplasms | |
| 650 | 2 | |a Neoplasms, Germ Cell and Embryonal | |
| 650 | 2 | |a Neoplasms, Nerve Tissue | |
| 650 | 2 | |a Adenocarcinoma, Papillary | |
| 650 | 2 | |a Gastrointestinal Diseases | |
| 650 | 2 | |a Digestive System Diseases | |
| 650 | 2 | |a Colonic Diseases | |
| 650 | 2 | |a Intestinal Diseases | |
| 650 | 2 | |a Lung Diseases | |
| 650 | 2 | |a Respiratory Tract Diseases | |
| 650 | 2 | |a Thyroid Diseases | |
| 650 | 2 | |a Endocrine System Diseases | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 1, Phase 2 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 11. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:04 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT03037385 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 04 | ||